Both programs have the potential to address multiple indications, offering broad development opportunities alone and in combination with Gileads portfolio
NEW YORK Ro is now working with Eli Lilly to launch the recently FDA-approved Zepbound (tirzepatide) KwikPen nationwide on its platform
Light protection GHK-Cu demonstrates significant light sensitivity due to copper-catalyzed photodegradation
If you do accidentally inject too much medication, this can cause unpleasant side effects and discomfort
The study received funding from Wellcome, Medical Research Council, European Union Horizon 2020 Programme, the National Institutes of Health (grants U01-DK105535, U01-DK085545 and UM-1DK126185), the National Institute for Health Research Oxford Biomedical Research Centre, the Canadian Institutes of Health Research, the Novo Nordisk Foundation, Boehringer Ingelheim and Diabetes Australia